Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).

Abstract: The present invention relates to compounds of Formula (I) or pharmaceutically acceptable enantiomers, salts, solvates or prodrugs thereof. The invention further relates to the use of the compounds of Formula (I) for the treatment of cystic fibrosis. The invention also relates to a process for manufacturing compounds of Formula (I).

Abstract: The invention relates to the use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2, R6 and R9, independently=halogen, a R—NH—, R—NH—NH—, NH2—R?—NH or R—NH—R?—NH— group, where R=straight or branched chain saturated or unsaturated alkyl, aryl, cycloalkyl, or heterocyclyl group, R?=straight or branched chain, saturated or unsaturated alkylene, arylene or cycloalkylene, R and R? each include 1 to 8 carbon atoms optionally substituted with one or more —OH, halogen, amino or alkyl groups, R2 furthermore may be a heterocycle optionally with a straight or branched chain saturated or unsaturated alkyl, aryl or cycloaryl or a heterocycle optionally substituted by one or more —OH, halogen, amino or alkyl groups, R9 furthermore may be a straight or branched chain saturated or unsaturated alkyl, aryl or cycloalkyl and R2 and R9 furthermore may be hydrogen with the exception

Abstract: The invention concerns the use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells, said derivatives corresponding to formula (I), wherein: R?H or C1 and the phenyl group comprises two substituents, or a pharmaceutically acceptable salt of said derivatives.

Abstract: A treatment of cystic fibrosis by administration of a pharmaceutically acceptable amount of the glucosidase inhibitor NB-DMJ (N-butyldeoxy-mannojirimycin).

Abstract: A method provides for the use of glycosidase inhibitors selected from compounds of general formula (1), wherein R1 represents a CH3 group, or CH2OH, R2 represents H or an alkyl group having 1-5 carbon atoms, or R1 and R2 together form a group having formula (II), with carbon in position (a) and nitrogen of formula (I) mentioned above, for the preparation of a medicament used to treat mucovisidosis. A corresponding product is also described.

Abstract: A method provides for the use of glycosidase inhibitors selected from compounds of general formula (1), wherein R1 represents a CH3 group, or CH2OH, R2 represents H or an alkyl group having 1-5 carbon atoms, or R1 and R2 together form a group having formula (II), with carbon in position (a) and nitrogen of formula (I) mentioned above, for the preparation of a medicament used to treat mucovisidosis. A corresponding product is also described.

Abstract: The invention relates to the use of benzo[c]quinolizinium derivatives for treating diseases that are linked to smooth muscle cell constriction, such as hypertension and asthma.

Abstract: The invention concerns pharmaceutical formulas designed for the treatment of diseases related to CFTR channel dysfunction, such as cystic fibrosis, asthma or diarrhoea. These formulas contain a molecule, coming in the form of a zwitterion at physiological pH, with the general formula: where X?N or P; and Y?O or S.

Abstract: The invention concerns the use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells, said derivatives corresponding to formula (I), wherein: R?H or C1 and the phenyl group comprises two substituents, or a pharmaceutically acceptable salt of said derivatives.

Abstract: The invention relates to paullone derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of general formula (1): wherein X?C?O, C—S—CH3, C—S, —C—NHOH, Z—C or N, Y— with the adjacent ring, a phenyl or thienyl group, the ring(s) of said derivatives being optionally substituted with one or more halogen atoms, hydroxy, alkylenehydroxy, alkynealkylenehydroxy, alkynehydroxycyclohexyl, alkyl, alkoxy, alkylenealkoxy, or alkylenecyano groups where the alkylene group is either saturated or unsaturated, the groups having a straight or branched chain with C1 to C18, said chain being optionally substituted with one or more hydroxy or amino groups, or one or more trifluoromethyl, —COM, —COOM, or —CH2COOM groups (where M=H, C1 to C18 straight or branched chain alkyl, optionally substituted with one or more hydroxy and/or amino groups) nitroso, or cyano, R5?H, or C1 to C5 alkyl and R12?H, or —C—CO2—(CH3)3 and the phy

Abstract: The invention relates to the use of pyrrolopyrazine derivatives for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2 and R3 independently=H, C1-C6 straight or branched chain optionally-substituted alkyl, R6=an aromatic ring Ar or cycloalkyl, optionally substituted, said cycloalkyl optionally substituted by an aryl group which may equally be substituted, R7=H, C1-C6 alkyl, (alk.)n-Hal, CH2—CH?CH2, CH2-cycloalkyl, CH2—Ar and Z=H or CH3.

Abstract: The invention relates to paullone derivaties for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivaties being of general formula (1): wherein X?C?O, C—S—CH3, C—S,—C—NHOH, Z?C or N, Y?with the adjacent ring, a phenyl or thiazolyl group, the ring(s) of said derivaties being optionally substituted with one or more halogen atoms, hydroxy, alkylenehydroxy, alkynealkylenehydroxy, alkynehydroxycyclohexyl, alkyl, alkoxy, alkylenealkoxy, or alkylenecyano groups where the alkylene group is either saturated or unsaturated, the groups having a straight or branched chain with C1 to C18, said chain being optionally substituted with one or more hydroxy or amino groups, or one or more trifluoromethyl, —COM, —COOM, or —CH2COOM groups (where M?H, C1 to C18 straight or branched chain alkyl, optionally substituted with one or more hydroxy and/or amino groups) nitroso, or cyano, R5?H, or C1 to C5 alkyl and R12?H, or —C—CO2—(CH3)3 and the physio

Abstract: The invention relates to the use of purine derivatives for the production of medicaments for the treatment of mucoviscidosis and diseases related to protein addressing errors in cells, said derivatives being of formula (I): where R2, R6 and R9, independently=halogen, a R—NH—, R—NH—NH—, NH2—R?—NH or R—NH—R?—NH— group, where R=straight or branched chain saturated or unsaturated alkyl, aryl, cycloalkyl, or heterocyclyl group, R?=straight or branched chain, saturated or unsaturated alkylene, arylene or cycloalkylene, R and R? each include 1 to 8 carbon atoms optionally substituted with one or more —OH, halogen, amino or alkyl groups, R2 furthermore may be a heterocycle optionally with a straight or branched chain saturated or unsaturated alkyl, aryl or cycloaryl or a heterocycle optionally substituted by one or more —OH, halogen, amino or alkyl groups, R9 furthermore may be a straight or branched chain saturated or unsaturated alkyl, aryl or cycloalkyl and R2 and R9 furthermore may be hydrogen with the exception

Abstract: The invention relates to the use of glycosidase inhibitors selected from compounds of general formula (1), wherein R1 represents a CH3 group, or CH2OH, R2 represents H or an alkyl group having 1-5 carbon atoms, or R1 and R2 together form a group having formula (II), with carbon in position (a) and nitrogen of formula (I) mentioned above, for the preparation of a medicament used to treat mucoviscidosis.

Abstract: The invention concerns pharmaceutical formulas designed for the treatment of diseases related to CFTR channel dysfunction, such as cystic fibrosis, asthma or diarrhoea. These formulas contain a molecule, coming in the form of a zwitterion at physiological pH, with the formula: where X?N or P; Y?O or S; R1 to R7 represent: —, H, or carbon chains, substituted or not, which may contain heteroatoms; except for betaine.

Abstract: The invention relates to the use of benzo[c]quinolizinium derivatives for treating diseases that are linked to smooth muscle cell constriction, such as hypertension and asthma.

Abstract: CFTR channel activator compounds from the benzo[c]quinolizinium family or families of compounds derived therefrom, as well as pharmaceutical compositions containing said compounds, and the uses thereof, particularly for treating cystic fibrosis, are disclosed.